Shire is paying $20 million up front to acquire rights to a drug that Parion Sciences has developed as a potential treatment for dry eye disease. The deal calls for Shire (NASDAQ: SHPG) to take the lead on further work on P-321, a compound that Durham, NC-based Parion has tested in early-stage clinical trials. If […]
What Our Clients Say
[ssba_hide]
[testimonials category="Testimonial" random=true limit="1"]
Press Releases and Whitepapers
Industry News & Articles
- Byju’s founder says his edtech startup, once worth $22B, is now ‘worth zero’
- The surprising way OpenAI could reportedly get out of its pact with Microsoft
- Former watch trader is now building the AWS of grid storage, Terralyr
- Amazon indicates employees can quit if they don’t like its return-to-office mandate
- Automattic offered employees another chance to quit — this time with nine months’ severance
- General Catalyst reportedly to back Saudi Arabian startup
- Stripe in talks to acquire Bridge for $1 billion
- Elon Musk’s X is changing its privacy policy to allow third parties to train AI on your posts
Sample Relationships
[logo-carousel id=relationships]
Notables
[logo-carousel id=notables]